InsiderTrades

Form 4 for MAZE Maze Therapeutics, Inc.

Accepted 2026-01-09 00:00:00 ET · period of report 2026-01-07 · accession 0002050172-26-000006 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-01-09 2026-01-07 MAZE Bernstein Harold Pres, CMO, R, D M - OptEx $10.42 +25.2K 25.2K New +$262.1K
D 2026-01-09 2026-01-07 MAZE Bernstein Harold Pres, CMO, R, D S - Sale+OE $40.20 -25.2K 0 -100% -$1.01M
D 2026-01-09 2026-01-07 MAZE Bernstein Harold Pres, CMO, R, D M - OptEx $0.00 -25.2K 312.4K -7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-01-07 M A 25,156 $10.42 25,156 D — —
2 Common Common Stock 2026-01-07 S D 25,156 $40.20 0 D — — (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.55 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3 Derivative Stock Option (Right to Buy) 2026-01-07 M D 25,156 $0.00 312,407 D $10.42 · — to 2032-10-26 25,156 Common Stock (F3) The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.